Consumer Advertising of Psychiatric Medications Biases the Public Against Nonpharmacological Treatment
In the United States, aWntidepressant medications are heavily promoted through direct-to-consumer advertising, which is regulated by the Food and Drug Administration (FDA). Advertisements for selective serotonin reuptake inhibitors frequently contain information inconsistent with the scientific evidence on the treatment of depression with antidepressants. The information presented serves to promote the use of antidepressants by biasing the public against nonpharmacological treatment of depression. While the FDA enforces regulations requiring fair and balanced presentation when comparing one medication to another, there appears to be no action taken against pharmaceutical companies that distort scientific evidence in order to disparage nonmedical approaches to depression.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Editorial
Publication date: 01 September 2005
More about this publication?
- Ethical Human Psychology and Psychiatry seeks to raise the level of scientific knowledge and ethical discourse, while empowering professionals who are devoted to principled human sciences and services unsullied by professional and economic interests.
- Information for Authors
- Membership Information
- Information for Advertisers
- Free Sample Issue
- Subscribe to this Journal
- Ingenta Connect is not responsible for the content or availability of external websites